The Biden administration proposed a rule for Medicare and Medicaid to cover the costs of weight-loss drugs for millions of Americans with obesity.

Medicare and Medicaid would cover weight-loss drugs like Wegovy and Ozempic under a new rule proposed by President Joe Biden on Tuesday, increasing access to the widely popular medications to millions of adults with obesity in the U.S., though the plan would likely face opposition under President-elect Donald Trump's second administration.

About 42% of U.S. adults are obese, the CDC says. GLP-1 medications have changed the picture for people hoping to reduce risks with obesity.

The Biden administration on Tuesday proposed requiring Medicare and Medicaid to cover anti-obesity drugs. Why it matters: The rule would expand access to the medications for millions of Americans struggling with obesity,

The Biden administration wants to expand coverage of anti-obesity medications to millions on Medicare, Medicaid.

President Joe Biden’s proposal to have GLP-1 weight-loss drugs such as Wegovy, Ozempic, Zepbound and Mounjaro covered by Medicare and Medicaid would help tackle the public-health crisis of obesity, but it would raise the costs for the government programs by billions of dollars per year.